22 results on '"Mackay, H"'
Search Results
2. OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer
3. 726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)
4. 788P Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches
5. 748P Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
6. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer
7. A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma
8. A phase II study of tomudex (T) in combination with epirubicin (E) and cisplatin (C) in patients with advanced oesophageal and gastric (OG) adenocarcinoma.
9. Phase Ii, Multicenter, Open-Label, Proof of Concept Study of Tasquinimod in Patients with Advanced Hepatocellular (Hcc), Ovarian (Oc), Renal Cell (Rcc) and Gastric (Gc) Carcinomas
10. Predictors of Hypersensitivity Reactions (Hsrs) in Patients Receiving Carboplatin-Based Chemotherapy for Ovarian Cancer
11. The Evaluation of Paclitaxel Hypersensitivity Reactions (Hsrs) Following the Discontinuation of Prophylactic Pre-Medications
12. Novel Pharmacogenetic Germline Candidates of Bevacizumab-Related Survival in the Icon7 Trial of Advanced Stage Ovarian Cancer
13. Genome-Wide Association Study (Gwas) Identifies Candidate Neurotoxicity Markers in Platinum-Taxane Treated Ovarian Cancer Patients in Icon7
14. A Phase 1/2 Study of Ipilimumab in Women with Metastatic or Recurrent Hpv-Related Cervical Carcinoma: a Study of the Princess Margaret and Chicago N01 Consortia
15. 1532P - The Evaluation of Paclitaxel Hypersensitivity Reactions (Hsrs) Following the Discontinuation of Prophylactic Pre-Medications
16. 938TiP - A Phase 1/2 Study of Ipilimumab in Women with Metastatic or Recurrent Hpv-Related Cervical Carcinoma: a Study of the Princess Margaret and Chicago N01 Consortia
17. 879PD - Novel Pharmacogenetic Germline Candidates of Bevacizumab-Related Survival in the Icon7 Trial of Advanced Stage Ovarian Cancer
18. 893P - Predictors of Hypersensitivity Reactions (Hsrs) in Patients Receiving Carboplatin-Based Chemotherapy for Ovarian Cancer
19. 480P - Phase Ii, Multicenter, Open-Label, Proof of Concept Study of Tasquinimod in Patients with Advanced Hepatocellular (Hcc), Ovarian (Oc), Renal Cell (Rcc) and Gastric (Gc) Carcinomas
20. 180P - Genome-Wide Association Study (Gwas) Identifies Candidate Neurotoxicity Markers in Platinum-Taxane Treated Ovarian Cancer Patients in Icon7
21. LBA33 ICON9: International phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
22. 737P Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.